- Home
- ALLY vs MRNA Comparison
ALLY vs MRNA Comparison
Compare ALLY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLY | MRNA |
|---|---|---|
| Founded | 1919 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 9.3B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALLY | MRNA |
|---|---|---|
| Price | $42.69 | $27.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 13 |
| Target Price | ★ $46.33 | $33.91 |
| AVG Volume (30 Days) | 2.7M | ★ 9.9M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 11.52 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $7,171,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | $20.26 | N/A |
| Revenue Next Year | $14.12 | $0.77 |
| P/E Ratio | $25.36 | ★ N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $29.52 | $22.28 |
| 52 Week High | $44.83 | $48.92 |
Technical Indicators
Market Signals| Indicator | ALLY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 60.85 |
| Support Level | $37.51 | $23.92 |
| Resistance Level | $41.77 | $26.00 |
| Average True Range (ATR) | 1.03 | 1.29 |
| MACD | 0.39 | 0.32 |
| Stochastic Oscillator | 93.52 | 99.82 |
Price Performance
Historical ComparisonAbout ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.